Gilead has gotten a new HIV preventive treatment, Yeztugo, approved, which consists of two injections a year, promising more effective prevention.
Lara Maior
Current Affairs
Foto Gilead Pharma
Always see our news on Google
Yeztugo, a drug developed by Gilead, has been authorized in the United States as a preventive treatment against HIV. It requires only two injections a year, unlike current treatments that require daily pills. While the treatment could revolutionize the fight against the AIDS epidemic, cost remains a crucial issue, with an estimated annual price tag of about $25,000. UNAIDS director Winnie Byanyima emphasized the importance of making the drug affordable to have a real impact in the fight against AIDS.
Sources
Tratament promiţător împotriva HIV-SIDA. Producătorii promit prețuri accesibil
Statele Unite autorizează un nou tratament preventiv, foarte promiţător, împotriva HIV, virusul care cauzează SIDA
FDA approves first twice-yearly injection that prevents HIV infection
US approves promising preventive HIV treatment
Groundbreaking twice-a-year HIV drug that could stop transmission approved
Latest News
19:51
The Senate extends until 2035 the ban on using antivirus software and IT equipment in public institutions
19:34
Concordia calls on the Government to eliminate IMCA in 2027 and set a firm deadline for VAT refunds
19:34
Eurobarometer: 72% of Europeans do not feel well informed about innovative foods, while 51% have a negative opinion
19:27
Health Minister Alexandru Rogobete announces measures to prevent disruptions in the supply of medicines
19:14
DIICOT is investigating three citizens of Belarus and Ukraine suspected of causing a fire near a defense factory in Brașov
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
